IGM Biosciences Book Value | IGMS

Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.

What is included in book value

Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.

Features of the metric

Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account.
Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market.
Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors.
Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.

Annual Book Value IGM Biosciences

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
48.2 M	203 M	287 M	245 M	382 M	240 M	-65.8 M	-40.5 M	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
382 M	-65.8 M	162 M

Quarterly Book Value IGM Biosciences

2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
101 M	698 K	78.9 M	122 M	161 M	254 M	259 M	239 M	287 M	328 M	375 M	205 M	245 M	286 M	322 M	356 M	382 M	382 M	382 M	382 M	240 M	240 M	240 M	240 M	-4.91 M	-4.91 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
382 M	-4.91 M	235 M

Book Value of other stocks in the Biotechnology industry

Issuer	Book Value	Price	% 24h	Market Cap	Country
Celsion Corporation CLSN	7.06 M	-	-6.63 %	$ 13.9 M	USA
FSD Pharma HUGE	5.1 M	-	5743.5 %	$ 69.7 M	Canada
Qilian International Holding Group Limited QLI	392 M	-	-6.08 %	$ 184 M	China
Happiness Biotech Group Limited HAPP	29 M	-	1.35 %	$ 17.8 M	China
Synthetic Biologics SYN	15.4 M	-	1.32 %	$ 16.2 M	USA
Dynavax Technologies Corporation DVAX	597 M	-	-	$ 2.02 B	USA
BioXcel Therapeutics BTAI	-95.5 M	$ 1.19	5.31 %	$ 14.5 M	USA
Burford Capital Limited BUR	3.13 B	$ 4.37	0.23 %	$ 958 M	Britain
I-Mab IMAB	1.72 B	-	-	$ 866 M	China
BeyondSpring BYSI	-24 M	$ 0.84	34.27 %	$ 34.5 M	USA
Corner Growth Acquisition Corp. COOL	1.67 M	-	-0.89 %	$ 114 M	USA
AgeX Therapeutics AGE	-37 K	-	-10.17 %	$ 12.2 K	USA
Alexion Pharmaceuticals, Inc. ALXN	253 M	-	-	$ 40.3 B	USA
Genfit SA GNFT	282 M	-	2.54 %	$ 160 B	France
Biophytis SA BPTS	12 M	-	-13.47 %	$ 169 M	France
Cerus Corporation CERS	65 M	$ 2.98	4.93 %	$ 568 M	USA
Compugen Ltd. CGEN	157 M	$ 2.41	4.17 %	$ 225 M	Israel
CureVac N.V. CVAC	697 M	-	-	$ 867 M	Germany
EyeGate Pharmaceuticals, Inc. EYEG	2.33 B	-	-1.52 %	$ 24.7 M	USA
Athira Pharma ATHA	27.8 M	-	-	$ 269 M	USA
BiondVax Pharmaceuticals Ltd. BVXV	99.6 M	-	0.74 %	$ 768 M	Israel
Abcam plc ABCM	727 M	-	-	$ 4.9 B	Britain
Завод ДИОД DIOD	-243 M	-	-	-	Russia
Galera Therapeutics GRTX	6.55 M	-	-32.59 %	$ 7.61 M	USA
Midatech Pharma plc MTP	11.4 M	-	-18.52 %	$ 27.3 M	Britain
Hepion Pharmaceuticals HEPA	2.67 M	-	-18.79 %	$ 39.3 K	USA
ARCA biopharma ABIO	472 M	-	1052.0 %	$ 415 M	USA
MorphoSys AG MOR	49 M	-	2.43 %	$ 254 M	Germany
Champions Oncology CSBR	4.07 M	$ 5.1	2.63 %	$ 70.5 M	USA
Affimed N.V. AFMD	97.2 M	-	-34.95 %	$ 21.5 M	Germany
AnPac Bio-Medical Science Co., Ltd. ANPC	-9.4 M	-	-1.58 %	$ 28.1 M	China
Celyad Oncology SA CYAD	19.7 M	-	-	$ 12.5 M	Belgium
Adial Pharmaceuticals ADIL	5.28 M	$ 3.98	1.86 %	$ 2.66 M	USA
Generation Bio Co. GBIO	86.2 M	-	-	$ 344 M	USA
Akero Therapeutics AKRO	750 M	-	-	$ 3.67 B	USA
AnaptysBio ANAB	364 M	$ 58.47	4.37 %	$ 1.68 B	USA
Anika Therapeutics ANIK	190 M	$ 21.5	1.56 %	$ 308 M	USA
Cyclacel Pharmaceuticals CYCCP	6.84 M	-	-4.36 %	$ 27 M	USA
Gracell Biotechnologies GRCL	1.38 B	-	-	$ 3.37 B	China
Aurinia Pharmaceuticals AUPH	581 M	$ 15.47	1.91 %	$ 2.08 B	Canada
GlycoMimetics GLYC	203 M	-	9357.83 %	$ 1.01 B	USA
Aeterna Zentaris AEZS	3.84 M	-	5.93 %	$ 314 M	Canada
AVROBIO AVRO	251 M	-	1083.1 %	$ 745 M	USA
BeiGene, Ltd. BGNE	4.36 B	-	0.49 %	$ 251 B	Cayman-islands
Bicycle Therapeutics plc BCYC	610 M	$ 3.9	0.24 %	$ 270 M	Britain
Beam Therapeutics BEAM	1.24 B	$ 26.75	0.91 %	$ 2.65 B	USA
AIkido Pharma AIKI	69.4 M	-	1.93 %	$ 17.4 M	USA
Aeglea BioTherapeutics AGLE	715 M	-	-	$ 1.01 B	USA
BioMarin Pharmaceutical BMRN	6.09 B	$ 67.36	0.99 %	$ 12.9 B	USA
Aptose Biosciences APTO	-27.2 M	-	-45.71 %	$ 1.2 M	Canada